An Official Website of the United States Government
SBIR TOPIC 294 PHASE I - DEVELOPMENT OF GLYCOSYLATION-SPECIFIC RESEARCH…
- Small Business Information
-
Woman-Owned: YesMinority-Owned: YesHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2011Title: SBIR TOPIC 294 PHASE I - DEVELOPMENT OF GLYCOSYLATION-SPECIFIC RESEARCH REAGENTS (ANTIBODIES AND APTAMERS)Agency: HHSContract: N43CO110073Award Amount: $147,520.00
Abstract:
Protein O-GlcNAcylation (N-acetylglucosamine modification), which decreases phosphorylation, plays a critical role in cell-cycle regulation, apoptosis and signal transduction. So far, ~120 O-GlcNAcylated human proteins have been found. To elucidate functions of O-GlcNAcylation, it is necessary to develop site-specific antibodies for O-GlcNAcylated proteins. Many pan-specific antibodies for O-GlcNAcylation are available. However, few site-specific antibodies for O-GlcNAcylated proteins have been successfullyproduced. During the Phase I study, we will synthesize multiple antigen peptides with various features against O-GlcNAcylation sites of c-myc and p53 to test effects of a specific peptide design on the sensitivity and specificity of the antibodies. Sensitivity and specificity of the antibodies will be determined to find out the best peptide design. We will explore utility of the O-GlcNAcylation site-specific antibodies using human breast cell lines, normal (MCF10A) and tumor cells (MCF-7 and N-ras and H-ras MCF10A) with and without treatment with various O-GlcNAcase inhibitors.Small Business Information at Submission:DETROIT RANDD, INC.
4683 RAVINE DR BLOOMFIELD HILLS, MI 48301-3640EIN/Tax ID: 383375464DUNS: N/ANumber of Employees: N/AWoman-Owned: YesMinority-Owned: YesHUBZone-Owned: No
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: |
Program Year/Program: 2011 / SBIR |
|
Agency Tracking Number: N43CO110073 |
Solicitation Year: 2011 |
Solicitation Topic Code: NCI |
Solicitation Number: |